Results 121 to 130 of about 2,555,654 (307)

Extracellular Vesicles‐Based Biological Macromolecule Delivery Systems: Biogenesis, Characterization, and Emerging Clinical Applications

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are nanoscale membrane‐bound structures that play a pivotal role in intercellular communication by transporting bioactive molecules, including proteins, lipids, nucleic acids, and organelles, between cells. Originating from the endosomal pathway, EVs reflect the physiological and pathological status of their parent
Emine İncilay Torunoğlu, Zeynep Betül Sarı, Muhammed Emin Sarı, Erdi Can Aytar   +3 more
wiley   +1 more source

Evaluating survival after allogeneic bone marrow transplant for chronic myeloid leukaemia in chronic phase: a comparison of transplant versus no transplant in cohort of 258 patients first seen in Italy between 1984 and 1986.

, 1993
Information on the outcome of allogeneic bone marrow transplant (BMT) for chronic myeloid leukaemia (CML) was previously provided by BMT centres or registries.
The Italian Cooperative Study Group on Chronic Myeloid Leukemia, LIBERATI, Anna Marina   +1 more
core  

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Nanomedicine‐driven innovations in postoperative cancer immunotherapy: Remodeling tumor microenvironment and precision delivery strategies

BMEMat, EarlyView.
Nanomedicine‐Driven Strategies for Suppressing Postoperative Tumor Recurrence. This schematic illustrates three pivotal nanomedical strategies that synergistically counteract recurrence by targeting residual disease and the immunosuppressive tumor microenvironment within the surgical cavity.
Lisong Pang, Zhuomin Wang, Zhenhua Jin, Ahmed H. Ghonaim, Hengcheng Zhang, Xinyu You, Jinzhuo Ning, Jiaqing Cao, Yang Liu   +8 more
wiley   +1 more source

Innovation of plant‐derived extracellular vesicles and interdisciplinary research: From discovery to biomedical applications

BMEMat, EarlyView.
Plant‐derived extracellular vesicles offer numerous advantages and are regarded as highly promising candidates in the field of biomedicine. Abstract Extracellular vesicles (EVs) are double‐membrane vesicular structures that can be secreted by nearly all living cells.
Zilin Li, Yi Wei, Ben Hu, Yafang Song, Xiaojia Chen, Nik Ahmad Nizam Nik Malek, Tongkai Chen   +6 more
wiley   +1 more source

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors [PDF]

, 2002
FLT3 mutations, either internal tandem duplications (ITDs) or aspartate residue 835 (D835) point mutations, are present in approximately one third of patients with acute myeloid leukemia (AML) and have been associated with an increased relapse rate.
Kottaridis, P.D., Gale, R.E., Bowen, D.T., Langabeer, S.E., Frew, M.E., Linch, D.C.   +5 more
core  

Bone marrow‐like viscosity affects imatinib resistance in chronic myeloid leukemia

Biotechnology Progress, EarlyView.
Physical cues such as microenvironmental viscosity have been recognized as important regulators in controlling cell functions. However, even though the bone marrow (BM) is a viscous tissue in which cells respond mechanically to both the matrix stiffness and the viscosity of surrounding fluid, the impact of microenvironmental viscosity on imatinib (IM ...
Tianjiao Zeng, Huajian Chen, Man Wang, Toru Yoshitomi, Naoki Kawazoe, Yingnan Yang, Guoping Chen   +6 more
wiley   +1 more source

A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia.

, 1999
BACKGROUND AND OBJECTIVE: Alpha-interferon (alphaIFN) can induce cytogenetic remissions in chronic myeloid leukemia (CML). Hemopoietic progenitors can be collected from the marrow in remission and utilized for autologous repopulation after high dose ...
Russo D, Alimena G, Rosti G, Saglio G, Mandelli F, LIBERATI, Anna Marina, Zuffa E, Martinelli G, Fanin R, the Italian Cooperative Study Group on Chronic Myeloid Leukemia, Meloni G, Baccarani M, Tura S, Testoni N   +13 more
core  

A case series of necrotizing periodontal diseases in hospitalized patients: What hasn't been said yet?

Clinical Advances in Periodontics, EarlyView.
Abstract Background Necrotizing periodontal diseases (NPDs) are uncommon and severe inflammatory conditions characterized by tissue necrosis, painful ulceration, and rapid clinical progression, frequently associated with systemic immunosuppression. Limited data exist regarding their clinical presentation and management in hospital settings.
Osmaria Letthycia Carvalho Leal, Fernanda Bortolotto, Mariana Cristina Manoel, Gabriela Silveira de Araújo, Ana Carolina Fragoso Motta, Leandro Dorigan de Macedo, Lara Maria Alencar Ramos Innocentini, Joab Cabral Ramos, Isabel Schausltz Pereira Faustino   +8 more
wiley   +1 more source

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

, 2008
BACKGROUND: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival.
Alimena G, Pane F, Saglio G, Specchia G, Alberti D, MARTINELLI, GIOVANNI, ROSTI, GIANANTONIO, Bocchia M, BASSI, SIMONA, Breccia M, Zuffa E, Rege Cambrin G, Miglino M, LUATTI, SIMONA, Varaldo R, TESTONI, NICOLETTA, Pungolino E, PALANDRI, FRANCESCA, BACCARANI, MICHELE, CASTAGNETTI, FAUSTO, MARZOCCHI, GIULIA, GIMEMA Working Party on Chronic Myeloid Leukemia, Ferrara F   +22 more
core   +1 more source